Story excerpt provided by Columbus Business First.
Written by Carrie Ghose.
Having helped raise $200 million for two Cincinnati pharmaceutical startups that went public, a father-son team has returned to Central Ohio for their latest startup – which has a long road ahead as it seeks to develop a treatment for pinkeye.
It’s the latest in a growing biotech focus for Rev1, which invests in and advises startups but through its history has tended more heavily toward software and medical devices.
Click here to read the complete article. Originally published November 28, 2017.